Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a single-segment biotechnology company focused on developing innovative therapies for severe autoimmune and inflammatory disorders. With its promising candidate, EQ504, exhibiting enhanced activity in UC patient cells and a diverse mechanism of action, it has the potential to offer life-changing therapeutics for patients. With a valuation framework based on potential acquisition and strong preclinical validation of AhR agonism, Equillium's optimistic financial outlook is reinforced by its low toxicity risk and potential for significant therapeutic index in treating refractory UC patients.

Bears say

Equillium is currently facing potential competition from Azora Therapeutics' AT-177, which has a higher colon-to-plasma ratio and may enter the market before EQ504. Additionally, there are potential clinical risks as EQ504 has not yet entered human testing and may not replicate the target engagement, safety, or efficacy observed from previous AhR modulators. Furthermore, while EQ504 may work well in UC patient cells, there is no guarantee that it will produce the same results in clinical trials. These risks may hinder Equillium's ability to successfully develop and market a potential treatment for severe autoimmune and inflammatory disorders, and may impact its future financial performance.

Equillium Inc (EQ) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.